title: New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials.
abstract: BACKGROUND
  Prognostic models have been developed to predict survival of patients with newly diagnosed glioblastoma (GBM). To improve predictions, models should be updated with information at the recurrence. We performed a pooled analysis of European Organization for Research and Treatment of Cancer (EORTC) trials on recurrent glioblastoma to validate existing clinical prognostic factors, identify new markers, and derive new predictions for overall survival (OS) and progression free survival (PFS).
  
  
  METHODS
  Data from 300 patients with recurrent GBM recruited in eight phase I or II trials conducted by the EORTC Brain Tumour Group were used to evaluate patient's age, sex, World Health Organisation (WHO) performance status (PS), presence of neurological deficits, disease history, use of steroids or anti-epileptics and disease characteristics to predict PFS and OS. Prognostic calculators were developed in patients initially treated by chemoradiation with temozolomide.
  
  
  RESULTS
  Poor PS and more than one target lesion had a significant negative prognostic impact for both PFS and OS. Patients with large tumours measured by the maximum diameter of the largest lesion (⩾42mm) and treated with steroids at baseline had shorter OS. Tumours with predominant frontal location had better survival. Age and sex did not show independent prognostic values for PFS or OS.
  
  
  CONCLUSIONS
  This analysis confirms performance status but not age as a major prognostic factor for PFS and OS in recurrent GBM. Patients with multiple and large lesions have an increased risk of death. With these data prognostic calculators with confidence intervals for both medians and fixed time probabilities of survival were derived.
authors.affiliation: EORTC Headquarters, Brussels, Belgium. thierry.gorlia@eortc.be
authors.forename: Thierry
authors.initials: T
authors.lastname: Gorlia
authors.forename: Roger
authors.initials: R
authors.lastname: Stupp
authors.forename: Alba A
authors.initials: AA
authors.lastname: Brandes
authors.forename: Roy R
authors.initials: RR
authors.lastname: Rampling
authors.forename: Pierre
authors.initials: P
authors.lastname: Fumoleau
authors.forename: Christian
authors.initials: C
authors.lastname: Dittrich
authors.forename: Mario M
authors.initials: MM
authors.lastname: Campone
authors.forename: Chris C
authors.initials: CC
authors.lastname: Twelves
authors.forename: Eric
authors.initials: E
authors.lastname: Raymond
authors.forename: Monika E
authors.initials: ME
authors.lastname: Hegi
authors.forename: Denis
authors.initials: D
authors.lastname: Lacombe
authors.forename: Martin J
authors.initials: MJ
authors.lastname: van den Bent
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000401:mortality* / Q000473:pathology; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D018572:Disease-Free Survival; D005260:Female; D005909:Glioblastoma / Q000401:mortality* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000473:pathology; D011336:Probability; D011379:Prognosis